GSK's malaria vaccine, Sanofi and Regeneron's Praluent win EU nods; India again rejects Roche's Valcyte patent claims;

@FiercePharma: India's drug and CRO manufacturing travails gather pace as New Delhi calls on diplomats to help. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Two Sandoz plants in Germany and 1 in India to be shuttered by Novartis next year. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind. Story | Follow @CarlyHFierce

> Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 drug, Praluent, has won a recommendation for European regulatory approval. Release

> GlaxoSmithKline's ($GSK) malaria vaccine, Mosquirix, has received a positive scientific opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). Release

> Indian authorities have for the second time rejected Roche's ($RHHBY) patent claims for Valcyte. Report

> Anthem ($WLP) said on Friday it would buy Cigna ($CI) in a deal valued at $54.2 billion to create the largest U.S. health insurer by membership. Report

> India's Lupin is buying U.S. peer GAVIS Pharmaceuticals for $880 million to revive U.S. growth. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Bard hit with FDA warning letter affecting its vena cava filters. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Stroke-fighting Watchman, SpyGlass endoscope fuel strong Q2 for Boston Sci. Article | Follow @VarunSaxena2

@EmilyWFierce: Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Wall Street not anticipating another suitor for Thoratec on heels of St. Jude's $3.4B bid. Story

> Stryker: M&A still top priority for cash, but spent only $92M in first half on acquisitions. More

> ViewRay goes public via reverse merger, raises almost $77M since IPO cancellation. Article

> Oxford Performance Materials gets FDA nod for 3-D printed spinal implant. Report

Biotech News

@FierceBiotech: Biogen targets new biotech deals after reporting sour numbers, R&D setbacks. More | Follow @FierceBiotech

@JohnCFierce: These days, when the FDA locks the door to a cancer drug, it's saying something -- $SNSS. Release | Follow @JohnCFierce

> Denali names Carole Ho its R&D head. Chutes & Ladders

> Neos pulls off a $72M IPO to push its ADHD drugs forward. Item

> Roche backs out of its $1B cancer deal with Molecular Partners. Report

And Finally... The U.S. could save up to $16 billion annually if it negotiated Medicare Part D prices with drugmakers, a new paper says. Paper (PDF)

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.